Adrienne G. Randolph, M.D., M.Sc., Associate Professor of Anaesthesia, Harvard Medical School and Senior Associate in Critical Care at Boston Children's Hospital, commented, "Acute Respiratory Failure is a major cause for the admission of children into the intensive care unit. There is a clear unmet medical need for better therapeutic options to help these children. A new medical therapy that reduces the duration of mechanical ventilation for patients with Acute Respiratory Failure would be considered clinically important."
Premature babies, or those that have passed meconium in utero depend on Sufraxin. It's either DSCO's drug or an animal derived alternative. Discovery owns this market segment. I expect quarter over quarter revenue growth year after year since there isn't an alternative.
I wonder if this has to do with getting Mass General up as a trial site? Fantastic news!
Another positive for Neuralstem.
One word - Daytraders. Serious investors however are accumulating shares, for they know what the future holds. So let the price fluctuate up and down 10% in a day, the trend higher is now established. Pay no attention to the amateurs.
Sure you could provide a large dose to non ambulatory patients, but the better route is to achieve approval by careful patient selection that maximizes CR and PFS.
Well, by the numbers there were 15 people in the Phase 1 trial. 1 appears to have shown a CR [complete response] (Ted Harada) - see stories online, and 5 appears to be demonstrating PR [partial response] and/or PFS [progression free survival]. That's a 40% PFS in ALS, which currently has no existing beneficial therapies. I suspect with the proper enrollment criteria they will see phase 2 results approaching 60-70% PFS. Should that happen the FDA would approve NSI-566 with just Phase 2 data given this is an Orphan Disease. CUR is significantly undervalued, marketcap on approval would easily exceed 1 Billion - 8x today's price.
Many large investors missed this one, and have been waiting for a pullback. How far back it goes, unclear, but "money" is waiting to enter. Retail investors won't miss this one twice. Choose your entry point accordingly.
Interesting time for PRAN. Certainly headed much higher.
Indeed it's excellent news for Astex. Unfortunately we just have a down day in the market, biotechs included. No worries though, I used it as a chance to buy additional shares at a discount. I feel even more confident doing so given the news. I expect some interesting price action next week.
When you can add a 3 month durable response benefit, to a heavily pretreated patient population who have relapsed, you call that a major success. SGI-110 looks very effective, and this is great news for the expansion trial.
Undervalued relative to revenue growth potential. Today's pullback makes it even more compelling. I also think they are at risk of being acquired by LIFE.
I've been wanting into GNMK for so long, but it never seemed to have a pullback. This is sweet! Thanks to whomever sold me shares.
Generally poster sessions for abstracts can go positive or negative, but seldom (actually I can't remember a time) where an Abstract was selected for an oral session and disappointed. Of course different oncologists may choose to interpret data presented differently, but the selection committee must have seen something they like in the Galaxy-1 abstract to select it for an oral slot.
Trying to reconcile that with an earlier post about the SNTA chart. I don't see how the 50DMA falls through the 200DMA. The fact that Synta is up for an Oral presentation is positive, I'd expect the data to follow, and the chart to reflect that. To me, we have a small buying window between now and Monday. I'd expect a steady climb into Friday, and a significant bounce Tuesday morning. Time will tell, but that's how I see it play out.
Institutional buying last quarter was also a positive sign. GLTA
Let us try to elevate the discourse on this board. The World Vaccine Congress & Expo meets next week in Washington. There is a discussion panel in the Agenda dedicated to RSV Vaccines. You can review the program agenda at the conference website. It's scheduled for 5:30 on Tuesday April 16th. There will be a joint presentation on RSV Vaccines and clinical update starting at 5:30pm. Dr Collins is from the National Institute of Health (NIH), and Dr Glenn (Chief Medical Officer of Novavax).
Google "World Vaccine Conference", then select the first link, then choose Conference Program at the bottom of the page to review.
I've been watching Cellceutix for some time now, and have been tempted to buy multiple times. I like the association with Dana Farber, and Scientific Advisory board comprised of prominent folks at Sloan Kettering. But I always had this lingering concern about purchasing and OTC stock. Today's ASCO 2013 acceptance of the Kevetrin poster was the piece of data I needed to make a buy decision. Seldom do you get in on the ground floor of a major paradigm shift in oncology treatment, but Cellceuitix at this level appears to afford that opportunity. I feel very comfortable my investment today will do quite well over the coming year.
Best of luck to all.
You can review his profile on Bloomberg. He's held executive level positions as Pfizer, Schering-Plough, and most recently Hospira. BA in Biochemistry and a MD/PhD. with residency at Mass General/Harvard Medical School. Sounds like the real deal. He must see something he likes at Synta, as he walked away from a 1.6 Million dollar compensation package at Hospira.